Swedish biopharmaceutical company Swedish Orphan Biovitrum AB (Sobi) (STO: SOBI) announced on Wednesday that it has entered into research collaboration involving a new Phase 2a clinical trial for Gamifant (emapalumab) intended for the treatment of interferon-gamma (IFN Gamma)-driven sepsis (IDS), to be presented at the International Symposium on Intensive Care and Emergency Medicine (ISICEM) Congress by Professor Evangelos Giamarellos-Bourboulis, from the Hellenic Institute for the Study of Sepsis.

IDS is a new endotype representing approximately 20% of sepsis patients and is characterised by detection of IFNy (above lower limit of detection) and elevated levels of the chemokine CXCL9.

Planned to be conducted at 24 sites in Greece, the EMBRACE phase 2a study will investigate the potential of Gamifant (emapalumab) in treating a subgroup of sepsis patients driven by the IDS endotype and absence of sepsis-induced immunoparalysis. The double-blind, randomised controlled trial was approved in March 2025.

The first trial sites have been initiated, and patient screening to identify eligible patients with IDS has started.